CD4 and gastric cancer: Tai et al. [24] pointed out that, after the patients with stage II gastric cancer received EEN based on the radical gastrectomy, the CD3+ and CD4+ levels of patients were 62.47 ± 3.64% and 42.18 ± 3.81%, which were significantly higher than 58.62 ± 3.49% and 36.34 ± 3.24% before treatment, suggesting that EEN can significantly improve the immune function of patients with gastric cancer after radical gastrectomy.